Company Interview / Neuren Pharmaceuticals eyes EU breakthrough

Key points:

Positive EU recommendation for DAYBUE in Rett syndrome with ratification expected by PilcherNeuren set for US$35m European milestone and higher ex-US royalty rates under Acadia dealUp to US$170m in European sales milestones plus approaching US$500m US sales triggerPhase 3 NNZ‑2591 “Koala” trial in Phelan‑McDermid syndrome seen as next major value driver

Jon Pilche, CEO of Neuren Pharmaceuticals (ASX:NEU) sets out a highly optimistic view on the recent positive regulatory recommendation in Europe for its lead Rett syndrome therapy, DAYBUE. Pilcher notes the drug is already approved in the United States by the FDA and has three years of real-world use, and describes the European committee’s reversal from an earlier rejection as a “fantastic outcome” for the Rett community. He expects formal European Commission ratification within about two months, calling it highly unusual for such recommendations not to be endorsed.

Pilcher highlights Europe and Japan as the most attractive markets outside the US for this orphan drug. He points to a US$35 million milestone payment to Neuren following the first commercial sale in Europe, expected in Germany, alongside higher royalty rates in Europe and Japan than in the US. Under Neuren’s global licence to Acadia Pharmaceuticals for DAYBUE, Pilcher states Neuren bears no commercial costs and instead receives tiered royalties plus significant sales-based milestone payments, including up to US$170 million in Europe.

On pipeline progress, Pilcher flags NNZ‑2591 for multiple neurodevelopmental disorders, led by Phelan‑McDermid syndrome, now in a phase 3 “Koala” trial in the US and Canada, which he views as central to Neuren’s long-term growth strategy.